RLYB News and Press, Rallybio Corporation From 03/11/24

Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will partici...

2024-02-07 11:54:39 ET More on Rallybio Rallybio shares jump 13% on restructuring, cash runway extension Rallybio posts early Phase 1 data for lead candidate in bleeding disorder Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Ral...

2024-02-06 10:00:02 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

2024-02-06 09:59:13 ET More on Rallybio Rallybio posts early Phase 1 data for lead candidate in bleeding disorder Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full ...

– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – Anticipated cost savings, including a 45% workforce reduction, ex...

-- Phase 2 Study for RLYB212 Expected to Initiate in 2H 2024 -- -- Company to Provide Update on Phase 2 Discussions with European Medicines Agency for RLYB212 in 1H 2024 -- -- Cash Runway Extended into 3Q 2025 -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biot...

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extens...

-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women -- -- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women -- Rallybio Corporation (Nasdaq: RLY...